Voyager Therapeutics (VYGR) Enterprise Value: 2015-2025
Historic Enterprise Value for Voyager Therapeutics (VYGR) over the last 11 years, with Sep 2025 value amounting to $50.1 million.
- Voyager Therapeutics' Enterprise Value rose 290.24% to $50.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$668.2 million, marking a year-over-year increase of 34.99%. This contributed to the annual value of $43.0 million for FY2024, which is 69.35% down from last year.
- Per Voyager Therapeutics' latest filing, its Enterprise Value stood at $50.1 million for Q3 2025, which was up 215.20% from -$43.5 million recorded in Q2 2025.
- Voyager Therapeutics' 5-year Enterprise Value high stood at $225.7 million for Q2 2023, and its period low was -$49.4 million during Q1 2025.
- Its 3-year average for Enterprise Value is $59.4 million, with a median of $59.2 million in 2024.
- Per our database at Business Quant, Voyager Therapeutics' Enterprise Value surged by 680.14% in 2022 and then slumped by 173.43% in 2025.
- Voyager Therapeutics' Enterprise Value (Quarterly) stood at -$29.7 million in 2021, then spiked by 493.12% to $116.7 million in 2022, then grew by 20.39% to $140.4 million in 2023, then plummeted by 69.35% to $43.0 million in 2024, then soared by 290.24% to $50.1 million in 2025.
- Its Enterprise Value stands at $50.1 million for Q3 2025, versus -$43.5 million for Q2 2025 and -$49.4 million for Q1 2025.